Angion’s leadership team has extensive experience across the discovery, development and commercialization of therapeutics for kidney disease. Angion is applying its deep scientific expertise to advance its pipeline to treat life-threatening conditions.

Jay Venkatesan, MD, MBA, President and Chief Executive Officer
Prior to Angion, Dr. Venkatesan served as President and Director of Alpine Immune Sciences (ALPN), which he co-founded as a Managing Partner of Alpine BioVentures. Previously, Dr. Venkatesan was the founder and portfolio manager of Ayer Capital, a global healthcare fund. Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed healthcare investments. He was also a consultant at McKinsey & Co. and a venture investor with Patricof & Co. Ventures (now Apax Partners). He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.

Itzhak Goldberg, MD, FACR, Founder, Executive Chairman and Chief Scientific Officer
Dr. Goldberg was formerly a faculty member at Harvard Medical School, Boston, MA, Radiation Oncologist-in-Chief for the North Shore-LIJ (Northwell) Health System, , NY, and Professor at the Albert Einstein College of Medicine, Bronx, NY. Dr. Goldberg has made seminal contributions in the field of Tyrosine Kinase Receptors and Hepatocyte Growth Factor research and has been the driving force within Angion since he started the company. Under Dr. Goldberg’s leadership Angion received continuous non-dilutive NIH, DOD and NSF grants and successfully raised Series A/B funding.

John F. Neylan, M.D. Senior Vice President and Chief Medical Officer
Prior to Angion, Dr. Neylan served as Chief Medical Officer of Keryx, a biopharmaceutical company focused on nephrology. Previously, Dr. Neylan served as Senior Vice President, Clinical Development, at Genzyme Corporation, focusing on specialty metabolic diseases. From 2000-2008, Dr. Neylan served as Vice President, Research and Development for Wyeth Research, overseeing the clinical development of transplantation therapeutics and providing medical affairs support to the transplant franchise.

Prior to joining industry, Dr. Neylan held prestigious positions in academia, including Professor of Medicine at Emory University and Assistant Professor of Medicine at University of California, Davis, serving at both institutions as Medical Director of the respective Renal Transplant Programs, with oversight of the clinical research programs. Dr. Neylan received his BS from Duke University and his MD from Rush Medical School in Chicago. He completed his Internal Medicine residency at Vanderbilt University and fellowships in Nephrology and in Transplantation and Immunogenetics at Brigham and Women’s Hospital, Harvard University. Dr. Neylan has a proven track record for successful INDs, NDA/BLAs, and MAAs involving NCEs, polymers, biologics and RNA-based therapeutics and has authored more than 70 scientific manuscripts and book chapters. He is Past-President of the American Society of Transplantation and past Board Member of the National Kidney Foundation, and a past Industry Representative on the FDA Cardiovascular and Renal Drugs Advisory Committee.

Kevin Norrett, MBA, Senior Vice President and Chief Commercial Officer
Kevin brings over 20 years of experience to Angion. Over the course of his career, he has become an expert at helping clinical stage companies transition to full commercialization. Most recently, Kevin was VP, Marketing, Market Access & Commercial Operations at Aimmune Therapeutics, where he helped build the commercial function and launch strategy. Prior to joining Aimmune, Kevin was VP, Market Access and Commercial Development at ZS Pharma (acquired by AstraZeneca), where he was instrumental in launching its first therapeutic in nephrology and cardiology. Before ZS Pharma, he held multiple leadership roles at Exelixis and Genentech across commercial strategy, market access and market planning. Kevin’s multi-faceted background also includes several years of finance and manufacturing experience through his time with SG Cowen’s health care investment banking team and with SyStemix (acquired by Novartis). Kevin earned an MBA from the Haas School of Business at the University of California, Berkeley, an MS in Biochemistry and Molecular Biology from University of California, Los Angeles and a BS in Biological Sciences from the University of California, Davis.

Elisha Y. Goldberg, MBA, Director of Business Development
Mr. Goldberg leads business developments efforts for Angion Biomedica. Primary responsibilities include capital raising, strategic partnerships, and licensing agreements. Mr. Goldberg previously founded Broadfire Technologies, a thin client architecture company run out of MIT’s Lab for Computer Science (LCS) under Dr. Michael Dertouzos. He has also worked in equities and investment banking for multiple financial institutions, including Goldman Sachs, in the United States and abroad. Mr. Goldberg received his MBA from Columbia Business School with a concentration in corporate finance in 2005.